logo-loader
viewOpen Orphan PLC

Open Orphan reports unprecedented growth opportunities and strong pipeline to build revenues

Open Orphan PLC's (LON:ORPH) Cathal Friel says they're targeting operational profitability by the third quarter of the year following its merger with hVIVO. Speaking to Proactive following the release of its full-year results Friel says they're seeing unprecedented growth opportunities as pharma focuses funding on Covid-19 and respiratory diseases.

Quick facts: Open Orphan PLC

Price: 15.25 GBX

AIM:ORPH
Market: AIM
Market Cap: £101.51 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan PLC: Proactive One2One Virtual Conference

Open Orphan PLC's (LON:ORPH) Cathal Friel presents at the Proactive One2One Virtual Conference. The company's a rapidly growing specialist CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. It...

2 weeks, 6 days ago

2 min read